The FDA and Biopure reached an agreement to conduct a series of animal tests designed to study those safety concerns and determine whether a new round of human testing could safely be initiated.
The U.S. Naval Medical Research Center, which had been collaborating with Biopure in the study of Hemopure, was granted $4 million in additional Congressional funding for the United States Navy to continue research and development of Hemopure.